2022

Tourette C., Dioh W., Margalef C., Azbekyan A., Lafont R., Dilda P., Mariani J., Del Signore S., Agus S., Van Maanen R., Veillet S. (2022). Biophytis BIO101 in Sarcopenia: results of the Phase 2 SARA-INT study. Oral presentation at 2^nd Geroscience Conference, Mar 24-25^th, Toulouse, France.

Tourette C., Dioh W., Margalef C., Azbekyan A., Rabut S., Dupont P., Lafont R., Dilda P., Mariani J., Agus S., Van Maanen R., Veillet S. (2022). Biophytis BIO101 in Sarcopenia: Results of the SARA Program. Oral presentation at ICFSR 2022, Boston Apr 20^th – 22^nd. The Journal of Frailty & Aging, in press

Tourette C., Dioh W., Margalef C., Azbekyan A., Rabut S., Dupont P., Lafont R., Dilda P., Mariani J., Agus S., Van Maanen R., Veillet S. (2022). BIO101 in age-related sarcopenia: Results of the SARA program. Oral presentation at 15^th SCWD international conference, Lisbon June 24^th-26^th. Journal of Cachexia, Sarcopenia and Muscle, in press

Veillet S. (2022). Discussing the use of Sarconeos (BIO101) for the treatment of an emerging age-related disease, Covid-19. 4^th Annual Longevity Therapeutics Summit, June 28^th-30^th, San Francisco

Combination of BIO101 with antisense oligonucleotide therapy demonstrates synergistic beneficial effects in severe SMA-like mice. Bézier C., Nazari Hashemi P., Cottin S., Lafont R., Veillet S., Charbonnier F., Dilda P.J., Latil M., Biondi O. Invited presentation at the Cure SMA 2022 conference in Anaheim, California, USA on June 16-19, 2022

20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. Lafont R., Serova M., Didry-Barca B., Raynal S., Guibout L., Dinan L., S. Veillet, Latil M., Dioh W., Dilda P.J. Article published in J. Mol. Endocrinol. 68(2), 77-87 https://jme.bioscientifica.com/view/journals/jme/68/2/JME-21-0033.xml